FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort
出版年份 2022 全文链接
标题
FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort
作者
关键词
Cancers and neoplasms, Fibroblast growth factor, Protein expression, Gastrointestinal tract, Immunostaining, Gastrointestinal cancers, Cell staining, Signal amplification
出版物
PLoS One
Volume 17, Issue 2, Pages e0264011
出版商
Public Library of Science (PLoS)
发表日期
2022-02-16
DOI
10.1371/journal.pone.0264011
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration
- (2021) Akira Ooki et al. Gastric Cancer
- FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma
- (2021) Yue Wang et al. Journal of Translational Medicine
- Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
- (2021) Christoph Röcken et al. Genome Medicine
- High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers
- (2020) Joon Young Hur et al. PATHOLOGY RESEARCH AND PRACTICE
- Gastric cancer
- (2020) Elizabeth C Smyth et al. LANCET
- FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
- (2017) Angela N. Bartley et al. JOURNAL OF CLINICAL ONCOLOGY
- Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancer
- (2017) Mikito Inokuchi et al. World Journal of Surgical Oncology
- The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
- (2017) Christine Böger et al. OncoImmunology
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
- (2016) Soomin Ahn et al. MODERN PATHOLOGY
- Identification of neutral tumor evolution across cancer types
- (2016) Marc J Williams et al. NATURE GENETICS
- The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study
- (2016) Yongxu Jia et al. OncoTargets and Therapy
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
- (2016) A. Pearson et al. Cancer Discovery
- Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
- (2016) Seyoung Seo et al. Oncotarget
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
- (2016) Christine Böger et al. Oncotarget
- Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma
- (2016) Ryuma Tokunaga et al. Oncotarget
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
- (2015) Nicholas McGranahan et al. CANCER CELL
- MET in gastric cancer - discarding a 10% cutoff rule
- (2015) Marie-Luise Metzger et al. HISTOPATHOLOGY
- Clinicopathological characteristics ofRHOAmutations in a Central European gastric cancer cohort
- (2015) Christoph Röcken et al. JOURNAL OF CLINICAL PATHOLOGY
- Targeted therapy for gastric cancer: Current status and future directions (Review)
- (2015) DAN-DAN YUAN et al. ONCOLOGY REPORTS
- Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer
- (2015) Nayoung Han et al. PATHOBIOLOGY
- FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
- (2014) X Su et al. BRITISH JOURNAL OF CANCER
- Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH
- (2014) Kakoli Das et al. CANCER LETTERS
- Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
- (2014) Akiko Kawano Nagatsuma et al. Gastric Cancer
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Characteristics of gastric cancer in Asia
- (2014) Rubayat Rahman WORLD JOURNAL OF GASTROENTEROLOGY
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- Prognostic and Putative Predictive Biomarkers of Gastric Cancer for Personalized Medicine
- (2013) Viktoria S. Warneke et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation
- (2013) Guy Betts et al. VIRCHOWS ARCHIV
- Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
- (2012) V. S. Warneke et al. ANNALS OF ONCOLOGY
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma
- (2012) Eun-Jung Jung et al. HUMAN PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now